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Abstract
Background: Mushrooms inspired the cuisines of many cultures and conventional medicaments for cancer.
However, a substantial number of mushroom species are yet unexplored, possessing an unknown chemical,
biological and pharmacological profiles. Fulviformes fastuosus is a terrestrial mushroom, which is commonly found in
Sri Lankan woodlands. The current study was aimed at isolation and characterization of a potent cytotoxic
compound from F. fastuosus and investigating the apoptotic effect induced by the active principle against cancer
and normal cell lines.
Methods: Bioactivity guided isolation of active principles from the methanol extract of F. fastuosus was performed
by a rapid extraction and isolation method using different chromatographic techniques. Potential cytotoxic
compound was identified using one and two dimensional nuclear magnetic resonance spectroscopy and mass
spectrometry. Isolated compound was screened for in vitro cytotoxicity against Hepatocellular carcinoma (HepG-2),
Muscle rhabdomyosarcoma (RD) and Rat Wistar liver normal (CC-1) cell lines using 3 4, 5-(dimethylthiazol-2-yl) 2-5-
diphenyl tetrazolium bromide (MTT) cell viability assay. Apoptotic features of cells were observed via microscopic
examination and ethidium bromide/acridine orange fluorescent staining.
Results: The interpretation of spectral data resulted in the identification of the chemical structure as ergosta-4,6,8
(14),22-tetraen-3-one (ergone). Ergone exhibited promising cytotoxic properties against RD cells with less
cytotoxicity effect on CC-1 cells. In addition, ergone also possesses a strong cytotoxic effect against HepG-2 cells
showing low toxic level for CC-1 cells. Apoptotic features of treated cells were detected via morphological
characterization and ethidium bromide/acridine orange staining.
Conclusion: The present study elaborates the isolation of a potent cytotoxic compound; ergone, from F. fastuosus
via a rapid and efficient isolation method. Importantly, ergone has exhibited greater cytotoxic activity against RD
cells with high selectivity index compared to cytotoxicity against HepG-2 cells. Ergone can be used in the
development of therapeutic strategies for curbing rhabdomyosarcoma.
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Background
Mushrooms have long been esteemed as edible and me-
dicinal provisions for humankind. From ancient time,
substances derived from mushrooms are considered as a
boundless source of anticancer agents [1, 2]. Among the
prevailing degenerative diseases in the globe, cancer has
become the most prevalent devastating human degen-
erative disease worldwide [3, 4]. In spite of the availabil-
ity of modern antineoplastic agents, the number of lives
taken by this malicious disease increases annually
around the globe. The recent advances in cancer therap-
ies have failed in making significant progress in reducing
the morbidity caused by cancer [5, 6]. In this perspec-
tive, the use of secondary metabolites derived from nat-
ural sources having promising cytotoxic properties in
the development of new and more effective anticancer
drugs are highly desirable.
Mushrooms provide potent beneficial effects on cancer
either directly as antioxidants or through prevention of
genetic alterations underlying cancer [7]. The secondary
metabolites derived from mushrooms have the potential
to play a leading role in the development of anticancer
drugs with minimal side effects [8, 9]. There are approxi-
mately 650 species of macrofungi that have been re-
ported to possess antitumor activity [10]. Calvacin was
the most commonly used anticancer compound isolated
from giant puffball mushrooms [11]. In addition, lenti-
nan, schizophyllan and krestin derived from mushrooms
are approved as prescription drugs for the treatment of
cancer in Japan [12]. Currently, fungal extracts and iso-
lated fungal fractions are also being used in the trad-
itional medicine for the treatment of cancer as adjuvants
to chemotherapy, surgery and radiotherapy [13, 14].
Despite the development of anticancer therapeutics
using mushrooms, a large proportion of mushroom spe-
cies in the world still remain scientifically unexplored
making this group one of the mostly untapped microbio-
tic source for novel drug leads in the anticancer pharma-
ceutical industry [15]. Intriguingly, the mycological
potential of tropical island Sri Lanka is attributable to fa-
vorable climatic conditions and floral diversity [16, 17].
However, ethnomycological research in Sri Lanka indi-
cates only a rare use of mushrooms as food or internal
medicinal provisions by indigenous practitioners in Sri
Lanka [18, 19]. Hence, the current study was aimed at
isolation and characterization of a potent cytotoxic com-
pound from Fulviformes fastuosus harvested from the
dry zone forest reserves in Sri Lanka. F. fastuosus be-
longs to the Hymenochaetaceae family, which is com-
monly found in dry zone woodlands in Sri Lanka.
Members of the Hymenochaetaceae family are known to
possess strong bioactive properties including antioxidant
and anticancer activity which is strongly attributed to
polyphenolic substances contained in the mushrooms
[20]. Since the polyphenolic secondary metabolites pro-
duced by F. fastuosus mushroom exhibit largely diverse
structural differences, the isolation and separation of
metabolites can be lengthy and tedious [21]. Therefore,
the methods of isolating bioactive compounds are gener-
ally optimized to a series of rapid, simple and efficient
bioactivity guided fractionations [22, 23].
Methods
Chemicals and equipment
Methanol, HCl, hexane, chloroform and ethyl acetate
were purchased from BDH Chemicals (Poole, England).
MTT (3-(4,5-Dimethylthiazol-2-Yl)-2,5-Diphenyltetrazo-
lium Bromide), Ethidium bromide, Cycloheximide, Isoamyl
alcohol, and Acridine orange were purchased from Sigma
Chemicals Co. (St. Louis, USA). All chemicals used were of
analytical grade.
Shimadzu UV 1601 UV visible spectrophotometer
(Shimadzu Corporation, Kyoto, Japan) was used to
measure the absorbance. Rotary evaporator (BUCHI
Rota vapor R-200) was used to dry the extracts of F. fas-
tuosus. Thin layer chromatography was carried out by
using pre coated silica gel 60 F 254 (20×20) cm
2
Aluminum backed commercial grade sheets. Chromato-
grams were visualized using UV radiator with 9815
series lamp (254–364 lambda). Nuclear magnetic reson-
ance (NMR) spectra were recorded on a Bruker avance
AV- 600 MHz spectrometer with a 5 mm cryoprobe.
Cells were incubated at 37 °C in a humidified CO2 in-
cubator (SHEL LAB/Sheldon manufacturing Inc. Corne-
lius, OR 97113, USA). Olympus (1X70-S1F2) inverted
fluorescence microscope (Olympus Optical Co. Ltd.
Japan) was used for the observation of cells and images
were captured using digital camera (MDC 200, USB 2.0,
2 M pixels CCD chip) connected to the microscope. De-
ionized water from LABCONCO (waterproplus) UV
ultra-filtered water system (LABCONCO Corporation,
Kansas city, Missouri 64132–2696) or distilled water was
used in all experiments.
Fungal material
The specimen of F. fastuosus was collected from the dry
zone forest reserves of Dambulla, Sigiriya, and Minneriya
in Sri Lanka and transported to the laboratory with proper
ventilation. The identity of the specimen was authenti-
cated by a botanist of Department of Plant Science,
Faculty of Science, University of Colombo, and molecular
studies confirmed the identity of the species (Genbank
Accession No.: KP757737). Voucher specimens were de-
posited at the same Institute (UOC:DAMIA: D27b).
Large scale extraction of fruiting bodies of F. fastuosus
Mature fruiting bodies of F. fastuosus were brush
cleaned, dried in the oven at 40 °C to a constant mass
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and pulverized. Shredded and ground mushroom mate-
rials of fruiting bodies from F. fastuosus (1 kg) were sub-
jected to sonication extraction with methanol (4 L), for
5–6 h at room temperature. Methanol extract was fil-
tered twice through Whatman No. 1 filter paper and
same extraction procedure was repeated for the residue.
Filtrates were combined and evaporated to dryness at
40 °C under reduced pressure using rotary evaporator to
remove methanol. The resulting dried methanol extract
was dissolved in distilled water (500 mL) and was parti-
tioned in to hexane, dichloromethane and ethyl acetate
(500 mL each), respectively. Ethyl acetate fraction of F.
fastuosus was evaporated in a rotary evaporator to be
used in subsequent fractionation and isolation of bio-
active components.
Fractionation, isolation and structure elucidation
of the bioactive component
Bioactivity guided isolation of active principles using
chromatographic techniques
The dried ethyl acetate fraction of F. fastuosus was dis-
solved in a minimum amount of methanol and mixed
with 5 g of silica gel (230–400 mesh, 60 Å). The result-
ing silica gel slurry was dried using rotary evaporator
and placed at the top of 10 mm diameter column filled
with silica gel to produce final bed height of 100 mm.
The column of silica was eluted, using a gradient solvent
system starting from 100% hexane to 1:1 hexane: ethyl
acetate (100 mL each in 5% step gradient). Based on the
bioactivity and TLC studies, the eluted fraction numbers
30–34 using 70: 30 hexane: ethyl acetate solvent system
were preferred for further isolation and purification of
active compound.
The combined fraction numbers 30–34 were concen-
trated to dryness at reduced pressure. Resulting residue
was dissolved in methanol and mixed with silica gel as
mentioned previously. Subsequently, the gel slurry was
introduced to a similar size (10 mm diameter; final bed
height of 100 mm) of normal phase silica column packed
with silica. The column of silica was eluted using a gra-
dient solvent system starting from 100% hexane to 75:25
hexane: ethyl acetate solvent system (1% step gradient).
Based on the bioactivity and TLC studies, the eluted
fractions number 21–25 using 91: 9 hexane: ethyl acetate
solvent system were subjected to preparative thin-layer
chromatography (developed twice with hexane/ethyl
acetate, 9:1). Subsequently, it resulted in 15 mg of a
white solid, which proved to be nearly pure by TLC ana-
lysis where compound was dissolved in CH3OH and
spotted on normal phase TLC plates using pet. ether/
ethyl acetate (3:l) mixture to give a consolidated under
254 nm UV lamp. Final purification of the compound
was achieved by recrystallization from methanol.
Identification and characterization of the compounds by
nuclear magnetic resonance (NMR) and mass
spectrometry (MS)
One and two dimensional NMR spectra, including 1H
NMR, 13C NMR, DEPT 13C NMR, COSY, HMQC,
HMBC and NOESY were recorded to obtain chemical
shift information of the active compound using CD3OD
as the solvent. Electrospray Ionization Mass Spectrom-
etry (EIMS) was performed to obtain the high resolution
mass spectrum.
Cell lines and cell culture
The RD, HepG-2 and CC-1 cell lines were used in the
determination of in vitro cytotoxicity of isolated com-
pound. Human muscle rhabdomyosarcoma (RD) and
Rat liver normal (CC-1) cell lines were obtained from
Medical Research Institute, Colombo 08. Human hepato
cellular carcinoma (HepG-2) cell line was obtained from
Dr. Panjwani Center for Molecular Medicine and Drug
Research, International Center for Chemical and Bio-
logical Sciences, University of Karachi. The cells were
cultured and preserved in the Department of Biochemis-
try and Molecular Biology until used them in cytotox-
icity experiments. The cells were cultured in DMEM
supplemented with 10% heat inactivated fetal bovine
serum (FBS), HEPES, 3% glutamine, sodium bicarbonate
and antibiotic (penicillin/streptomycin). All the cultured
cell lines were incubated at 37 °C in a humidified CO2
incubator.
In vitro cytotoxicity and identification of the
apoptotic features of treated cells with isolated
compound from F. fastuosus
MTT assay
The RD and Hep-G2 cells were seeded in 24-well plates
at the density of 2 × 105 cells per well and CC-1 cells
were cultured at a density of 2 × 103 cells per well
followed by incubation at 37 °C for overnight in a hu-
midified CO2 incubator. Test compound was dissolved
in methanol: DMSO (1:1) mixture and confluent mono-
layers were treated with different concentrations of the
above prepared test solution followed by incubation at
37 °C for 24 h. In all experiments, cycloheximide
(5 mM, 50 μL) was used as the positive control and
negative control contained the growth media and the
solvent mixture used to dissolve the test compound.
Subsequently, the cells treated with test solution were
subjected to MTT cell viability assay. The culture
medium was replaced with fresh growth medium (1 mL)
and MTT (5 mg/mL; 100 μL) was added to each well.
The cells were incubated at 37 °C for 3 h and the growth
medium was aspirated carefully. The remaining forma-
zan crystals were solubilized in 750 μL of 0.05 M HCl
prepared in 2-propanol and absorbance was measured at
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570 nm. Percentage cell viability was determined using
the formula: Percentage cell viability = [(Absorbance of
untreated cells -Absorbance of treated cells)/Absorbance
of untreated cells]*100 (Additional file 1). The net absorb-
ance from the wells of the negative control was considered
as the 100% viability. EC50 values were determined by re-
gression analysis (R2 > 0.95) of the corresponding dose re-
sponse curves of percentage inhibition of cell viability and
concentration of the test solution.
Morphological determination
The apoptotic morphological changes of treated cells
with different concentrations of the test solution over
24 h were observed via microscopic examination of cells.
Morphological changes were compared with negative
and positive controls under the light microscope.
Acridine orange-Ethidium bromide (AO/EB) staining
Apoptotic morphology of treated cells was detected and
distinguished by acridine orange-ethidium bromide
(AO/EB) fluorescent staining. The staining method was
performed via introducing a mixture of fluorescent dyes,
acridine orange and ethidium bromide in 1:1 ratio on
treated cells. RD, HepG-2 cancer cells (2 × 103 cells/well)
and CC-1 cells (2 × 102 cells/well) were seeded in cham-
ber slides. Resulting confluent layers were treated with
different concentrations of the test solution and incu-
bated at 37 °C for 24 h. The adherent cells were washed
with 200 μL of PBS and 2 μL of the dye mixture con-
taining ethidium bromide (100 mg/mL) and acridine
orange (100 mg/mL) in 1:1 ratio was placed on each
well of the chamber slide. Chamber slides were exam-
ined immediately under the florescence microscope and
images were captured.
Calculations and statistics
All experiments were performed in triplicate and values
given are representative for at least three independent
experiments. All the results of the experiments were
expressed as the mean ± standard deviation (Mean ± SD).
The results were statistically analyzed by T test using
Microsoft Excel. A p-value less than 0.05 were consid-
ered as statistically significant.
Ethical approval
The requirement for ethical approval was waived.
Result
Identification of compound isolated from the extract of F.
fastuosus
Purified compound was obtained from the extract of
Fulviformes fastuosus to yield 4 mg of the compound as
white colour needle shaped crystals. The EIMS showed
molecular ion peak at m/z 392. Its molecular formula,
C28H40O was determined by HREI MS which showed
molecular ion peak m/z at 392.3090 (calcd for C28H40O =
392.3079). The 1H-NMR spectrum (Table 1) displayed sig-
nals for six methyl groups at δ 0.83 (3H, d, J = 7.5 Hz, H3-
26), 0.85 (3H, d, J = 7.5 Hz, H3-26), 1.03 (3H, s, H3-18),
1.06 (3H, s, H3-19), 1.07 (3H, d, J = 7.5 Hz, H3-21), 1.08
(3H, d, J = 7.5 Hz, H3-28). Additionally, the
1H-NMR
spectrum displayed resonances for five downfield signals
at δ 5.26 m (H-22), 5.27 m (H-23), 5.70 s (H-4), 6.10 d
(J = 9.6 Hz, H-6), 6.71 d (J = 9.6 Hz, H-7). The structure
of compound was further confirmed by 2D-NMR spectra
(COSY, HSQC, HMBC, NOESY) (Additional file 2). The
spectral data were in good agreement with those of
ergosta-4,6,8 (14),22-tetraen-3-one which was previously
reported by Youla et al., (1992) [24]. Hence, the inter-
pretation of above spectral data (Table 1) resulted in
the identification of the chemical structure of purified
Table 1 13C-and 1H-NMR chemical shift values of ergone (ppm,
CD3OD, 150 and 600 MHz, respectively)




4 123.2 5.70 s
5 167.9 –
6 125.3 6.10 d (9.6)















22 133.7 5.26 m
23 130.8 5.27 m
24 44.4 –
25 35.4 2.12
26 20.5 0.83 d (7.5)
27 21.7 0.85 d (7.5)
28 20.4 1.08 d (6.4)
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compound as ergosta-4,6,8 (14),22-tetraen-3-one or
ergone (Fig. 1).
In vitro Cytotoxicity of ergone
As evident in Fig. 2a, ergone demonstrated a potent
cytotoxic effect on RD cells with remarkably lower IC50
value of 1.49 ± 2.74 mM. Moreover, Fig. 2a depicts a
dose dependent increase of percentage inhibition of cell
viability over a concentration range of 0.01–1.5 μg/mL
of test solution. The maximum of 74% inhibition of cell
growth was observed at 5.0 μg/mL of the test solution.
Ergone also exhibited a strong cytotoxicity effect against
HepG-2 cells by showing an IC50 of 68.32 ± 2.49 mM in
a dose dependent manner (Fig. 2b). Positive control (cy-
cloheximide) exhibited 76.35 ± 3.12% growth inhibition
at the concentration (5 mM, 50 μL) used.
The IC50 value determined for the mean of the three
independent sample preparations of ergone dissolved in
methanol: DMSO (1:1) against normal mammalian cell
line (CC-1) was 22.99 ± 2.42 mM (Fig. 2c). Thereby, se-
lectivity index shown by the compound ergone against
RD cells becomes 15.44 indicating less cytotoxic effect
on normal cells according to the definition of Prayong et
al., (2008) [25].
Morphological changes
The morphological changes observed on RD, HepG-2,
and CC-1 cells after the treatment with ergone are rep-
resented in Figs. 3, 4 and 5. The morphology of un-
treated cells and cells treated with the lower
concentrations of ergone appeared in elongated shape.
The cells treated with higher doses exhibited apoptotic
features including cellular shrinkage, oval or irregular
shape, fragmented nuclei, apoptotic bodies formation
and condensed cytoplasm. The concentration of ergone
in which cells started to display apoptotic features varied
depending on the type of the cell line.
Ethidium bromide/acridine orange staining
As evident in Figs. 6, 7 and 8, the apoptotic morphology
was detected by acridine orange-ethidium bromide (AO/
EB) fluorescent staining of RD, HepG-2 and CC-1 cell
lines treated with ergone.
As demonstrated in Figs. 6, 7 and 8, nuclei stained
with green colour demonstrate live cells while greenish
yellow shows early apoptotic cells. Condensed Orange
red nuclei indicate late apoptotic cells whereas red
colour exhibits dead cells. The untreated cells (negative
control) and treated cells with the lower concentrations
of the compounds appeared with the normal nuclei pre-
sented in bright green. Cells treated with higher doses of
the compounds and 5 mM concentration of positive
control showed unique features of apoptosis such as
chromatin condensation, nuclear fragmentation, pres-
ence of apoptotic bodies and blebbing formation, are of
significance upon examination of stained cells with eth-
idium bromide/acridine orange. Chromatin condensa-
tion and nuclear fragmentation were predominantly
observed apoptotic features for treated cells with high
concentrations of the compounds. In addition, number
of apoptotic cells was gradually increased with the treat-
ment dose.
Discussion
The past decade has witnessed the overwhelming inter-
est in isolation and characterization of bioactive com-
pounds from medicinal mushrooms due to the fact that
natural products of mushroom origin are found to pos-
sess a remarkably high pharmacological index [26, 27].
The mounting evidences from various scientific studies
regarding the applications of mushroom extracts and
Fig. 1 Structural Formula of Ergone
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Fig. 2 The percentage inhibition of cell viability against (a) RD (b) Hep-G2 (c) CC-1 cell line as determined by MTT assay, after 24 h treatment with
the ergone. The graphical data are represented as mean ± SD of three independent experiments (n = 3)
Fig. 3 Light micrographs of RD cell line after 24 h of incubation with ergone at different concentrations. a- 0.1 μM; (b)- 2 μM; (c)- 50 μM;
(d)- Cycloheximide as the positive control (5 mM; 50 μL) (×40)
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Fig. 4 Light micrographs of Hep-G2 cell line after 24 h of incubation with ergone at different concentrations. a- 5 mM; (b)- 50 mM; (c)- 80 mM;
(d)- Cycloheximide as the positive control (5 mM; 50 μL) (×40)
Fig. 5 Light micrographs of CC-1 cell line after 24 h of incubation with ergone at different concentrations. a- 2 mM; (b)- 10 mM; (c)- 40 mM;
(d)- Cycloheximide as the positive control (5 mM; 50 μL) (×40)
Fernando et al. BMC Complementary and Alternative Medicine  (2016) 16:484 Page 7 of 11
Fig. 6 Apoptotic morphology detection by acridine orange-ethidium bromide (AO/EB) fluorescent staining of RD cell line treated with ergone
dissolved in methanol: DMSO (1:1). a- Negative control; (b)- 2 μM; (c)- 5 μM; (d)- Cycloheximide as the positive control (5 mM; 50 μL) (×40). Arrows
indicate formation of apoptotic bodies
Fig. 7 Apoptotic morphology detection by acridine orange-ethidium bromide (AO/EB) fluorescent staining of HepG-2 cell line treated with
ergone dissolved in Methanol: DMSO (1:1). a- Negative control; (b)- 80 μM; (c)- 130 μM; (d)- Cycloheximide as the positive control (5 mM; 50 μL)
(×40). Arrows indicate formation of apoptotic bodies
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substances in the development of anti-cancer therapeu-
tics unarguably make it a fast-track research area worth
mass attention. Consequently, mushroom consumption
has been shown to prevent the development of cancer
later in life with studies reporting an inverse correlation
between mushroom intake and the risk of developing
cancer [28, 29]. In this perspective, the current study has
been succeeded in the isolation of a potent cytotoxic
compound namely ergone which is derived from a Sri
Lankan mushroom. Ergone is an essential steroid, which
belongs to ergosterol group [30]. Since it is necessary to
expand the current extraction protocols with the in-
creasing interest in mushroom metabolites, a novel and
easy isolation method have been optimized in the
current invention to isolate ergone with high reproduci-
bility. Specifically, the extraction and isolation process of
ergone is rapid, simple, inexpensive and comprehensive
with respect to the constituents to be isolated.
In vitro cytotoxic activity of isolated product ergone
against RD and HepG-2 cells were determined by MTT
cell viability assay, which is a well-established colorimet-
ric method to assess the cell proliferation and cell viabil-
ity. It has been revealed that ergone isolated from F.
fastuosus has promising cytotoxic properties against RD
cells with less cytotoxicity effect on normal CC-1 cells
(SI = 15.44). Moreover, ergone also showed strong
cytotoxic activity against HepG-2 cells being less toxic
to normal CC-1 cells. However, cytotoxic activity of
ergone against RD cell line is significantly high com-
pared to HepG-2 cells (p < 0.05). The apoptotic features
observed via microscopic examination of treated cells
and AO/EB fluorescent staining evidenced the apoptosis
induced by ergone against RD and HepG-2 cells. Mor-
phological characterization and ethidium bromide/acrid-
ine orange staining of treated cells revealed that the cell
death induced by ergone has mediated through apop-
tosis. It strengthens the results obtained via MTT cell
viability assay.
Our previous study has revealed that the crude metha-
nolic extract of F. Fastuosus possess cytotoxic activity
against RD cell line with an IC50 of 14.72 ± 1.56 μg/mL
[31]. Ergone’s cytotoxic activity against RD cell line
(584.01 ± 2.74 ng/mL) has become twenty five times
greater than the cytotoxic activity shown by the crude
extract of F. fastuosus in terms of IC50 against RD cell
line. Hence, it can be concluded that the promising cyto-
toxic activity of F. fastuosus could be largely contributed
by the remarkably high cytotoxic activity of ergone. In
addition, mangiferin, a strong anticancer compound iso-
lated from Mangifera indica has shown an inhibitory
concentration (IC50) of 33.40 μg/mL against RD cells
[32]. Interestingly, antiproliferative activity shown by
Fig. 8 Apoptotic morphology detection by acridine orange-ethidium bromide (AO/EB) fluorescent staining of CC-1 cell line treated with ergone
dissolved in Methanol: DMSO (1:1). a- Negative control; (b)- 6 μM; (c)- 50 μM; (d)- Cycloheximide as the positive control (5 mM; 50 μL). This figure
denotes the results of at least 3 independent experiments (Original magnification 40×). Arrows indicate formation of apoptotic bodies
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ergone was found to be significantly greater (p < 0.05)
than the anticancer activity of mangiferin. Importantly,
the present discovery has become the first study of iso-
lating ergone from F. fastuosus and it is appeared to be
an essential anti-tumor drug lead against rhabdomyosar-
coma. Currently, the treatment regime of rhabdomyosar-
coma comprises of chemotherapy and radiation along
with surgery while producing adverse side effects includ-
ing neurotoxicity, hepatotoxicity and cardiotoxicity [33].
Hence, the use of afore kind of natural products against
RD is an extremely promising strategy for remedy of
rhabdomyosarcoma. Intriguingly, most of the mush-
rooms belong to the family of Hymenochaetaceae have
long been used as edible forms [34]. Therefore, ergone,
which is isolated from family Hymenochaetaceae, has a
greater potential to act safely in human body without
creating any complications. In addition, this fact was
supported by the high selectivity index shown by the
ergone against RD sarcoma cells.
Conclusion
Ergone is a potent cytotoxic compound against RD and
HepG-2 cancer cell lines being less toxic to normal CC-
1 cells. Moreover, ergone has shown significantly greater
cytotoxic activity against RD cell line compared to
HepG-2 cell line. The present findings imply the propen-
sity of ergone to develop as a safe pharmaceutical com-
position against rhabdomyosarcoma with a high efficacy
for inducing cell death of RD while being less toxic to
normal cells. Intriguingly, above discovery provides a sci-
entific proof of the traditional awareness in using natural
compounds isolated from medicinal mushrooms as anti-
cancer agents.
Additional files
Additional file 1: A summary of the data obtained from MTT assay.
(XLSX 10 kb)
Additional file 2: 1D, 2D and mass spectra. (DOCX 12600 kb)
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CH3OH: Methanol; COSY: H-H correlation spectroscopy; DEPT
13C
NMR: Distortionless enhancement polarization transfer carbon nuclear
magnetic resonance spectroscopy; DMSO: Dimethyl sulfoxide;
EIMS: Electrospray ionization mass spectrometry; HCl: Hydrochloric acid;
HMBC: Heteronuclear multiple-bond correlation spectroscopy;
HMQC: Heteronuclear multiple-quantum correlation spectroscopy; MTT: 3 4,
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